Mykofenolsyre Accord (Mycophenolic Acid)

Mykofenolsyre Accord is an antimetabolite immunosuppressant used in conditions where immune modulation is required.

• Organ transplant rejection: helps prevent graft rejection by inhibiting lymphocyte proliferation.
• Lupus nephritis: reduces renal inflammation and proteinuria in patients with systemic lupus erythematosus.
• Autoimmune disease management: may be employed to control disease activity in selected autoimmune disorders when other therapies are insufficient.

• Mycophenolic Acid selectively and reversibly inhibits inosine monophosphate dehydrogenase (IMPDH), the key enzyme for de novo guanosine nucleotide synthesis in lymphocytes. This depletion of guanosine nucleotides impairs DNA replication, leading to reduced proliferation of activated T‑ and B‑lymphocytes and thereby dampening the immune response.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Diarrhea: watery stools, sometimes leading to dehydration.
• Headache: transient cranial discomfort.
• Hypertension: elevated blood pressure readings.
• Infections: increased susceptibility to bacterial and viral infections.
• Fatigue: generalized lack of energy.

Serious or Rare Side Effects

• Bone marrow suppression: leukopenia, anemia, or thrombocytopenia.
• Opportunistic infections: including fungal or viral pathogens.
• Hepatic toxicity: elevated liver enzymes or hepatitis.
• Malignancy: increased risk of certain cancers with long‑term use.
• Severe gastrointestinal ulceration or perforation.
• Progressive multifocal leukoencephalopathy (PML).

Mykofenolsyre Accord requires careful monitoring and patient counseling.

• Monitor blood counts: perform regular complete blood count tests to detect bone‑marrow suppression.
• Assess renal function: check serum creatinine and glomerular filtration rate periodically.
• Avoid pregnancy: drug is contraindicated in pregnancy (Category D); use effective contraception.
• Live vaccines: do not administer live attenuated vaccines while on therapy.
• Dose adjustments: consider reduced dosing in hepatic impairment.
• Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Mykofenolsyre Accord can interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid)

• Azathioprine: additive bone‑marrow suppression; concurrent use should be avoided.
• Live vaccines: increased risk of infection; avoid co‑administration.
• Antacids containing aluminum or magnesium: reduce drug absorption; separate dosing by at least 2 hours.

Moderate Interactions (Monitor Closely)

• Cyclosporine or tacrolimus: may increase mycophenolic acid exposure; monitor drug levels.
• Warfarin: potential for enhanced anticoagulant effect; check INR more frequently.
• Rifampin: induces metabolism, decreasing drug concentrations; consider dose adjustment.